Patents by Inventor Yves Chantigny

Yves Chantigny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF
    Publication number: 20230357221
    Abstract: Heterocyclic compounds of Formula I: and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Application
    Filed: June 28, 2023
    Publication date: November 9, 2023
    Inventors: Yves GAREAU, Stéphane GINGRAS, Yves CHANTIGNY, Gaoqiang YANG, Guy SAUVAGEAU, Irène BACCELLI, Anne MARINIER
  • COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS
    Publication number: 20230338429
    Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
    Type: Application
    Filed: May 19, 2023
    Publication date: October 26, 2023
    Applicant: Universite De Montreal
    Inventors: Bruno SIMONEAU, Yves CHANTIGNY, Jonathan YEH, Guy SAUVAGEAU, Anne MARINIER
  • Heterocyclic mitochondrial activity inhibitors and uses thereof
    Patent number: 11760754
    Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: September 19, 2023
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
  • Compounds and use thereof in the expansion of stem cells and/or progenitor cells
    Patent number: 11696928
    Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 11, 2023
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Bruno Simoneau, Yves Chantigny, Jonathan Yeh, Guy Sauvageau, Anne Marinier
  • HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF
    Publication number: 20210387980
    Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Application
    Filed: November 2, 2018
    Publication date: December 16, 2021
    Inventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
  • COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS
    Publication number: 20200323923
    Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
    Type: Application
    Filed: November 1, 2018
    Publication date: October 15, 2020
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Bruno SIMONEAU, Yves CHANTIGNY, Jonathan YEH, Guy SAUVAGEAU, Anne MARINIER
  • Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
    Patent number: 9493456
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defined herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: November 15, 2016
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
  • IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
    Publication number: 20160296507
    Abstract: Disclosed is a compound of Formula I: or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Réjean RUEL, Yves CHANTIGNY, Anne MARINIER, Patricia RENE, Michel BOUVIER
  • PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
    Publication number: 20150197520
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defined herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
  • Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
    Patent number: 9018395
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: April 28, 2015
    Assignee: Université de Montréal
    Inventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
  • PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
    Publication number: 20140057894
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Application
    Filed: January 26, 2012
    Publication date: February 27, 2014
    Applicant: Universite De Montreal
    Inventors: Michel Bouvier, Anne Marinier, Rejean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
  • IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
    Publication number: 20130165426
    Abstract: Disclosed is a compound of Formula I or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors.
    Type: Application
    Filed: July 5, 2011
    Publication date: June 27, 2013
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Réjean Ruel, Yves Chantigny, Anne Marinier, Patricia Rene, Michel Bouvier
  • Modulators of the glucocorticoid receptor
    Patent number: 7553877
    Abstract: The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R1—R25 are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.
    Type: Grant
    Filed: July 13, 2006
    Date of Patent: June 30, 2009
    Assignee: Pfizer, Inc.
    Inventors: Yves A. Chantigny, Edward F. Kleinman, Ralph P. Robinson
  • SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
    Publication number: 20070293530
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I), and racemic and scalemic mixtures, diastereomers and enantiomers thereof: or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, prodrug or complex thereof, wherein Y, L, Z, W, M, Ra, Rb and Rc are as defined in the specification.
    Type: Application
    Filed: June 14, 2007
    Publication date: December 20, 2007
    Applicant: METHYLGENE INC.
    Inventors: David Smil, Silvana Leit, Alain Ajamian, Martin Allan, Yves Chantigny, Robert Deziel, Eric Therrien, Amal Wahhab, Sukhdev Manku
  • Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase
    Publication number: 20070155730
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein A, B, D, E, X1, X2, X3, X4 and n are as defined in the specification.
    Type: Application
    Filed: August 25, 2006
    Publication date: July 5, 2007
    Applicant: METHYLGENE, INC.
    Inventors: Silvana Leit, Amal Wahhab, Martin Allan, David Smil, Pierre Tessier, Robert Deziel, Yves Chantigny
  • Inhibitors of histone deacetylase
    Publication number: 20060264415
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.
    Type: Application
    Filed: March 31, 2006
    Publication date: November 23, 2006
    Inventors: Silvana Leit de Moradei, Pierre Tessier, David Smil, Amal Wahhab, Robert Deziel, Sukhdev Manku, John Mancuso, Eric Therrien, Martin Allan, Yves Chantigny, Alain Ajamian, Patrick Beaulieu
  • Modulators of the glucocorticoid receptor
    Patent number: 7138406
    Abstract: The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R1–R25 are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: November 21, 2006
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Yves A. Chantigny, Edward F. Kleinman, Ralph P. Robinson
  • Modulators of the Glucocorticoid Receptor
    Publication number: 20060247264
    Abstract: The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R1—R25 are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.
    Type: Application
    Filed: July 13, 2006
    Publication date: November 2, 2006
    Inventors: Yves Chantigny, Edward Kleinman, Ralph Robinson
  • Modulators of the glucocorticoid receptor
    Publication number: 20040138262
    Abstract: The present invention provides compounds of the formula 1
    Type: Application
    Filed: July 8, 2003
    Publication date: July 15, 2004
    Applicant: Pfizer Inc.
    Inventors: Yves A. Chantigny, Edward F. Kleinman, Ralph P. Robinson